Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis
The Oncologist · 06.02.2025 · 30 (2)
DOI: 10.1093/oncolo/oyae209 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.09.2024. Verfasst von Jianing Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun 130021, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The efficacy of radiotherapy (RT) combined with targeted therapy and immunotherapy in treating hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) is still unclear. This study investigated the efficacy and safety of RT combined with targeted therapy and immunotherapy in HCC with PVTT. Materials and Methods Seventy-two patients with HCC with PVTT treated with tyrosine kinase inhibitor (TKI) plus programmed cell death protein-1 (PD-1) inhibitor with or without RT from December 2019 to December 2023 were included. After propensity score matching (PSM) for adjusting baseline differences, 32 pairs were identified in RT + TKI + PD-1 group (n = 32) and TKI + PD-1 group (n = 32). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs).
Results
Median OS (mOS) in RT + TKI + PD-1 group was significantly longer than TKI + PD-1 group (15.6 vs. 8.2 months, P = .008). Median PFS (mPFS) in RT + TKI + PD-1 group was dramatically longer than TKI + PD-1 group (8.1 vs. 5.2 months, P = .011). Patients in TKI + PD-1 + RT group showed favorable ORR and DCR compared with TKI + PD-1 group (78.1% vs. 56.3%, P = .055; 93.8% vs. 81.3%, P = .128). Subgroup analysis demonstrated a remarkable OS and PFS benefit with TKI + PD-1 + RT for patients with main PVTT (type III/IV) and those of Child-Pugh class A. Multivariate analysis confirmed RT + TKI + PD-1 as an independent prognostic factor for longer OS (HR 0.391, P = .024) and longer PFS (HR 0.487, P = .013), with no mortality or severe TRAEs.
Conclusion
RT combined with TKI and PD-1 inhibitor could significantly improve mOS and mPFS without inducing severe TRAEs or mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun 130021, People's Republic of China.
- Department of Interventional Therapy, The First Hospital of Jilin University, Changchun 130021, People's Republic of China.
- Department of Cardiology, The First Hospital of Jilin University, Changchun 130021, People's Republic of China.
ORCID-Profile: Lijuan Ding
Zitieren
APA
Ma, J., Zhang, H., Zheng, R., Wang, S., & Ding, L. (2025). Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis. The Oncologist, 30(2). https://doi.org/10.1093/oncolo/oyae209
Vancouver
Ma J, Zhang H, Zheng R, Wang S, Ding L. Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis. The Oncologist. 2025;30(2). doi:10.1093/oncolo/oyae209
BibTeX
@article{Ma2025,
author = {Ma, Jianing and Zhang, Haifeng and Zheng, Ruipeng and Wang, Shudong and Ding, Lijuan},
title = {Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {2},
doi = {10.1093/oncolo/oyae209}
}
EUVIMED